Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).

We are recommending PepsiCo and Target for investment in 2025 due to suppressed valuations and potential for growth amid ...

Walmart's investment thesis has evolved from a stodgy dividend-paying value stock to a high-octane growth stock. With over 50 ...

British American Tobacco Malaysia is impacted by new e-cigarette laws. See why BATMF stock remains a Hold despite challenges in the vapor market.

Canadians have another $7,000 in Tax-Free Savings Account (TFSA) contribution space in 2025. One popular TFSA investing ...